Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder

Bartzokis, George; Lu, Po H.; Turner, Jana; Mintz, Jim; Saunders, C. Scott

doi:10.1016/j.biopsych.2004.11.039

Cited by 166 publications

(98 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three patients who abandoned treatment could not be contacted. Using GLM for repeated measures we did not detect any effect of the between subject factor (F (8,18) The mean aripiprazole maximum tolerated dosage was 9.6 (± 4.3) mg/day, with a dose range of 3.75 to 15 mg/day.…”

Section: Resultsmentioning

confidence: 85%

See 1 more Smart Citation

Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial

Mello

Costa

Schoedl

et al. 2008

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: Post traumatic stress disorder is frequent in the general population (F = 11.247, p = 0.001); (F = 8.931, p = 0.011); (F = 8.633, p = 0.012); (F = 10.127 p = 0.007); (F = 1.580, p = 0.042 7 (± 23,1) e 51,4 (± 31,4) (F = 11,247, p = 0,001);7 (± 13,4) e 25,4 (± 18,2) (F = 8,931, p = 0,011);4 (± 0,45) e 2,27 (± 0,57) (F = 8,633, p = 0,012);6 (± 14,11) e 94,01 (± 25,06) (F = 10,127 p = 0,007);06 (± 11,6) e 21,35 (± 12,6) (F = 1,580, p = 0,042

show abstract

Section: Resultsmentioning

confidence: 85%

“…Olanzapine, 8 risperidone 9 and quetiapine 10 were shown to improve scores of Clinician Administered Posttraumatic Scale (CAPS) total scale and subscales, as well as psychotic symptoms. In addition, there is evidence that 36-46% of patients with PTSD also suffer from psychotic symptoms.…”

Section: Introductionmentioning

confidence: 99%

Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial

Mello

Costa

Schoedl

et al. 2008

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Previously, a number of small single-site studies suggested that atypical antipsychotic agents were effective adjunctive treatment for PTSD patients who had poor responses to first-line SSRIs or SNRIs [60][61][62][63][64]. A recent large-scale multisite trial of risperidone as an adjunctive agent for poor or partial responders to SSRI/ SNRI antidepressants showed no benefit (in comparison with a placebo group) [18].…”

Section: Initiating Effective Pharmacotherapymentioning

confidence: 99%

Pharmacotherapy for posttraumatic stress disorder: Review with clinical applications

Jeffreys

Capehart²,

Friedman³

2012

JRRD

View full text Add to dashboard Cite

Abstract-Posttraumatic stress disorder (PTSD) is a prevalent psychiatric diagnosis among veterans and has high comorbidity with other medical and psychiatric conditions. This article reviews the pharmacotherapy recommendations from the 2010 revised Department of Veterans Affairs/Department of Defense Clinical Practice Guideline (CPG) for PTSD and provides practical PTSD treatment recommendations for clinicians. While evidence-based, trauma-focused psychotherapy is the preferred treatment for PTSD, pharmacotherapy is also an important treatment option. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors and the selective serotonin-norepinephrine reuptake inhibitor venlafaxine. Second-line agents have less evidence for their usefulness in PTSD and carry a potentially greater side effect burden. They include nefazodone, mirtazapine, tricyclic antidepressants, and monoamine oxidase inhibitors. Prazosin is beneficial for nightmares. Benzodiazepines and antipsychotics, either as monotherapy or used adjunctively, are not recommended in the treatment of PTSD. Treating co-occurring disorders, such as major depressive disorder, substance use disorders, and traumatic brain injury, is essential in maximizing treatment outcomes in PTSD. The CPG provides evidence-based treatment recommendations for treating PTSD with and without such cooccurring disorders.

show abstract

“…As such, risperidone has the capacity to reduce positive and negative symptoms of PTSD, such as, delusions, hallucinations, thought disorder, hostility, social and emotional withdrawal and aggression, among others (Kozaric-Kovacic, Pivac, Muck-Seler, & Rothbaum, 2005). Two RCTs (Hamner, Faldowski et al, 2003;Bartzokis et al, 2004) and two open-label trials (David, De Faria, & Mellman, 2006;Kozaric-Kovacic et al, 2005) demonstrate the positive effect of risperidone in the treatment of refractory PTSD. However, Rothbaum et al (2005) failed to find any benefit of risperidone on the primary CAPS outcome.…”

Section: Risperidonementioning

confidence: 99%

A Review of Interventions for Treatment-Resistant Posttraumatic Stress Disorder

Katz¹,

Stein²,

Richardson³

et al. 2011

Different Views of Anxiety Disorders

View full text Add to dashboard Cite

Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder

Cited by 166 publications

References 27 publications

Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial

Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial

Pharmacotherapy for posttraumatic stress disorder: Review with clinical applications

A Review of Interventions for Treatment-Resistant Posttraumatic Stress Disorder

Contact Info

Product

Resources

About